Market Cap 186.52B
Revenue (ttm) 36.75B
Net Income (ttm) 7.71B
EPS (ttm) N/A
PE Ratio 14.85
Forward PE 14.67
Profit Margin 20.98%
Debt to Equity Ratio 6.24
Volume 3,450,800
Avg Vol 2,531,624
Day's Range N/A - N/A
Shares Out 539.71M
Stochastic %K 87%
Beta 0.42
Analysts Sell
Price Target $355.74

Company Profile

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of my...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 805 447 1000
Fax: 805 447 1010
Address:
One Amgen Center Drive, Thousand Oaks, United States
clan
clan Jun. 5 at 9:25 PM
$MNKD Lasagna said there is another drug in development that has not yet been disclosed publically. What might it be? Whose drug might it be? Another new collaboration? Hmmmm?🤔 $MRK $AMGN $NVS
0 · Reply
roblake29
roblake29 Jun. 5 at 5:59 PM
$AMGN Read my latest analysis here. Hint, I've upgraded the stock on improving fundamentals. GLTA. https://seekingalpha.com/article/4912197-amgen-time-for-an-upgrade-yes-i-think-so
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 5:29 PM
$AMGN 370 test Monday
0 · Reply
JFDI
JFDI Jun. 5 at 5:23 PM
$AMGN follow thru
0 · Reply
Pravo_Koirala
Pravo_Koirala Jun. 5 at 1:44 PM
🐺 𝐓𝐇𝐄 𝐇𝐔𝐍𝐓 · 𝟎𝟔.𝟎𝟓.𝟐𝟔 · 𝐭𝐡𝐞 𝐠𝐚𝐭𝐞 𝐡𝐞𝐥𝐝 🌑 Jobs day. Hot print, 172K vs 85K. Regime reads risk-on but choppy, VIX 15, dollar firming. My scanner ran the board and surfaced its three sharpest edges. 🩸 Then it rejected all three. $BAC long, edge 7.39, 76% win. $AMGN long, 7.34. $WFC short, 7.32. Every one scored high. Every one killed by the gate — historical win-rate in their bucket sits below the 50% floor. High score, bad ground. No entry. 🎯 That's the whole discipline. A high conviction score is not a green light. The Wilson gate asks one question, has this setup actually paid more than half the time in this regime? When the answer is no, the model says no, and I listen. 🦅 The best hunt today was the one I didn't take. Three baited traps, scored pretty, refused on the math. On a day the tape is choppy and the Fed just lost its reason to cut, sitting flat is a position. The crowd chases the score. The hunter checks the ground under it. 📊 Observational. No position. NFA. #wavervanir #volanx #quant #optionsflow #riskmanagement
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 12:36 PM
$AMGN Maintain at Buy GS Price Target 425
0 · Reply
biolover
biolover Jun. 5 at 6:07 AM
$VKTX  CEO confirmed high awareness of their obesity program across industry and high interest by BP .. essentially what we have been hearing from the likes of $ABBV $AMGN $NVO $BMY and likely others. Also his expectation for low GI issues with maintenance dosing in trial . Early cohort on this trial entered in Oct - Nov time line so good portion would have been already on monthly or q 2 wk dosing by now. Small trial and CEO should get timely reporting. This CEO has a history of giving clues as he hinted about higher GI issues with oral phase 2 ( turned out due to 4 large pills for 120 mg ) wks prior to reporting. Now he is upbeat on maintenance tolerability. Sounds like at least no vomit issue with first 21 wks despite more rapid escalation vs phase 3. ( I know there is no vomit issue with the vanquish program at more than one site as posted earlier ) I think all the slight delay with amylin likely to get oral amylin going. Based on his previous statements.
0 · Reply
MarketBeat
MarketBeat Jun. 5 at 5:03 AM
https://marketbeat.com/a/8693206/ $AMGN Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
0 · Reply
oppel
oppel Jun. 4 at 8:50 PM
$AMGN good finish. more to come tomorrow
0 · Reply
khalid44
khalid44 Jun. 4 at 7:56 PM
0 · Reply
Latest News on AMGN
Amgen price target lowered to $389 from $425 at Goldman Sachs

2026-06-05T12:55:40.000Z - 13 hours ago

Amgen price target lowered to $389 from $425 at Goldman Sachs


European Commission approves Amgen’s Imdylltra for ES-SCLC

2026-06-01T20:35:14.000Z - 4 days ago

European Commission approves Amgen’s Imdylltra for ES-SCLC


AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

May 29, 2026, 4:01 PM EDT - 7 days ago

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE


This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

May 27, 2026, 11:45 AM EDT - 9 days ago

This Boring Income Portfolio Strategy Could Unlock 300%+ Upside

V


Amgen price target lowered to $427 from $432 at Piper Sandler

2026-05-14T11:05:39.000Z - 22 days ago

Amgen price target lowered to $427 from $432 at Piper Sandler


Amgen upgraded to Buy from Hold at Freedom Broker

2026-05-07T12:36:50.000Z - 4 weeks ago

Amgen upgraded to Buy from Hold at Freedom Broker


Amgen downgraded to Hold from Buy at Erste Group

2026-05-05T10:28:11.000Z - 4 weeks ago

Amgen downgraded to Hold from Buy at Erste Group


Erste downgrades Amgen on declining sales growth

2026-05-05T10:26:09.000Z - 4 weeks ago

Erste downgrades Amgen on declining sales growth


Amgen price target lowered to $340 from $351 at Guggenheim

2026-05-04T11:27:17.000Z - 4 weeks ago

Amgen price target lowered to $340 from $351 at Guggenheim


Amgen price target raised to $307 from $304 at BofA

2026-05-01T14:09:13.000Z - 5 weeks ago

Amgen price target raised to $307 from $304 at BofA


Amgen price target raised to $332 from $326 at Morgan Stanley

2026-05-01T13:41:41.000Z - 5 weeks ago

Amgen price target raised to $332 from $326 at Morgan Stanley


Amgen price target raised to $327 from $325 at Truist

2026-05-01T13:07:02.000Z - 5 weeks ago

Amgen price target raised to $327 from $325 at Truist


Amgen Earnings Call Transcript: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 5 weeks ago

Amgen Earnings Call Transcript: Q1 2026


Amgen Slides: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 5 weeks ago

Amgen Slides: Q1 2026


Amgen Earnings release: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 5 weeks ago

Amgen Earnings release: Q1 2026


Amgen Quarterly report: Q1 2026

Apr 30, 2026, 4:30 PM EDT - 5 weeks ago

Amgen Quarterly report: Q1 2026


Amgen Posts Higher First-Quarter Profit, Revenue

Apr 30, 2026, 4:19 PM EDT - 5 weeks ago

Amgen Posts Higher First-Quarter Profit, Revenue


Amgen reports Q1 adjusted EPS $5.15, consensus $4.77

2026-04-30T20:14:00.000Z - 5 weeks ago

Amgen reports Q1 adjusted EPS $5.15, consensus $4.77


AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

Apr 30, 2026, 4:01 PM EDT - 5 weeks ago

AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS


Notable companies reporting after market close

2026-04-30T17:29:42.000Z - 5 weeks ago

Notable companies reporting after market close

AAPL CLX DXCM FIVN FSLR ILMN MTZ


FDA proposes to withdraw Amgen's rare autoimmune disease drug

Apr 27, 2026, 9:04 PM EDT - 5 weeks ago

FDA proposes to withdraw Amgen's rare autoimmune disease drug


AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS

Apr 24, 2026, 4:01 PM EDT - 6 weeks ago

AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS


Amgen Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 6 weeks ago

Amgen Proxy statement: Proxy filing


Amgen Proxy statement: Proxy filing

Apr 15, 2026, 8:00 AM EDT - 7 weeks ago

Amgen Proxy statement: Proxy filing


Amgen's lung cancer drug tarlatamab wins China approval

Apr 10, 2026, 4:10 AM EDT - 2 months ago

Amgen's lung cancer drug tarlatamab wins China approval


FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths

Mar 31, 2026, 11:16 AM EDT - 2 months ago

FDA Says Amgen's Tavneos Linked to Liver Injuries, Deaths


GSK and Amgen to add medicines to TrumpRx, Fox Business reports

Mar 13, 2026, 8:27 PM EDT - 3 months ago

GSK and Amgen to add medicines to TrumpRx, Fox Business reports

GSK


Amgen Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 3 months ago

Amgen Transcript: Leerink Global Healthcare Conference 2026


AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

Mar 4, 2026, 4:01 PM EST - 3 months ago

AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND


Amgen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 1:10 PM EST - 3 months ago

Amgen Transcript: TD Cowen 46th Annual Health Care Conference


Why Amgen Stock Is Paying Off Big For Long-Term Investors

Feb 4, 2026, 10:50 AM EST - 4 months ago

Why Amgen Stock Is Paying Off Big For Long-Term Investors


Amgen Earnings Call Transcript: Q4 2025

Feb 3, 2026, 4:30 PM EST - 4 months ago

Amgen Earnings Call Transcript: Q4 2025


Amgen Annual report: Q4 2025

Feb 3, 2026, 4:30 PM EST - 4 months ago

Amgen Annual report: Q4 2025


Amgen Earnings release: Q4 2025

Feb 3, 2026, 4:30 PM EST - 4 months ago

Amgen Earnings release: Q4 2025


Amgen Slides: Q4 2025

Feb 3, 2026, 4:30 PM EST - 4 months ago

Amgen Slides: Q4 2025


clan
clan Jun. 5 at 9:25 PM
$MNKD Lasagna said there is another drug in development that has not yet been disclosed publically. What might it be? Whose drug might it be? Another new collaboration? Hmmmm?🤔 $MRK $AMGN $NVS
0 · Reply
roblake29
roblake29 Jun. 5 at 5:59 PM
$AMGN Read my latest analysis here. Hint, I've upgraded the stock on improving fundamentals. GLTA. https://seekingalpha.com/article/4912197-amgen-time-for-an-upgrade-yes-i-think-so
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 5:29 PM
$AMGN 370 test Monday
0 · Reply
JFDI
JFDI Jun. 5 at 5:23 PM
$AMGN follow thru
0 · Reply
Pravo_Koirala
Pravo_Koirala Jun. 5 at 1:44 PM
🐺 𝐓𝐇𝐄 𝐇𝐔𝐍𝐓 · 𝟎𝟔.𝟎𝟓.𝟐𝟔 · 𝐭𝐡𝐞 𝐠𝐚𝐭𝐞 𝐡𝐞𝐥𝐝 🌑 Jobs day. Hot print, 172K vs 85K. Regime reads risk-on but choppy, VIX 15, dollar firming. My scanner ran the board and surfaced its three sharpest edges. 🩸 Then it rejected all three. $BAC long, edge 7.39, 76% win. $AMGN long, 7.34. $WFC short, 7.32. Every one scored high. Every one killed by the gate — historical win-rate in their bucket sits below the 50% floor. High score, bad ground. No entry. 🎯 That's the whole discipline. A high conviction score is not a green light. The Wilson gate asks one question, has this setup actually paid more than half the time in this regime? When the answer is no, the model says no, and I listen. 🦅 The best hunt today was the one I didn't take. Three baited traps, scored pretty, refused on the math. On a day the tape is choppy and the Fed just lost its reason to cut, sitting flat is a position. The crowd chases the score. The hunter checks the ground under it. 📊 Observational. No position. NFA. #wavervanir #volanx #quant #optionsflow #riskmanagement
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 5 at 12:36 PM
$AMGN Maintain at Buy GS Price Target 425
0 · Reply
biolover
biolover Jun. 5 at 6:07 AM
$VKTX  CEO confirmed high awareness of their obesity program across industry and high interest by BP .. essentially what we have been hearing from the likes of $ABBV $AMGN $NVO $BMY and likely others. Also his expectation for low GI issues with maintenance dosing in trial . Early cohort on this trial entered in Oct - Nov time line so good portion would have been already on monthly or q 2 wk dosing by now. Small trial and CEO should get timely reporting. This CEO has a history of giving clues as he hinted about higher GI issues with oral phase 2 ( turned out due to 4 large pills for 120 mg ) wks prior to reporting. Now he is upbeat on maintenance tolerability. Sounds like at least no vomit issue with first 21 wks despite more rapid escalation vs phase 3. ( I know there is no vomit issue with the vanquish program at more than one site as posted earlier ) I think all the slight delay with amylin likely to get oral amylin going. Based on his previous statements.
0 · Reply
MarketBeat
MarketBeat Jun. 5 at 5:03 AM
https://marketbeat.com/a/8693206/ $AMGN Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference
0 · Reply
oppel
oppel Jun. 4 at 8:50 PM
$AMGN good finish. more to come tomorrow
0 · Reply
khalid44
khalid44 Jun. 4 at 7:56 PM
0 · Reply
albiegf13
albiegf13 Jun. 4 at 7:51 PM
$IBRX The Saudis are quietly accumulating as is $AMGN...
4 · Reply
Game_Day
Game_Day Jun. 4 at 7:45 PM
$ABBV 🔥 expected to reach higher tomorrow + $AMGN $HOOD gone
0 · Reply
Options_Destroyer
Options_Destroyer Jun. 4 at 7:40 PM
$ABBV $AMGN $HIMS will continue higher . keep them all
0 · Reply
oppel
oppel Jun. 4 at 4:40 PM
$AMGN if 345 holds it will go further next days
0 · Reply
oppel
oppel Jun. 4 at 3:28 PM
$AMGN 345 come on….
0 · Reply
capitalthinktank
capitalthinktank Jun. 4 at 2:18 PM
QUANTINUUM $QNT.X just went public today and the IPO was massively oversubscribed (reportedly ~20x demand). This is the first true quantum computing pure-play to hit a traditional IPO market, and pricing came in strong at $60 per share, above the expected range. Deal details: $1.68B raised on 28M shares, with an additional greenshoe option. Valuation lands around $15.6B, making it one of the largest quantum pure-plays right behind $IONQ. What stands out isn’t just the IPO hype — it’s the positioning. Backed by $HON and Cambridge Quantum, with early enterprise exposure including $NVDA and $AMGN, plus government-linked support. The tech is still early, still loss-making, but the market is clearly repricing quantum from “research story” to “strategic infrastructure layer.” Quantum names already ran hard in 2026, but this IPO feels like another liquidity trigger for the entire sector.
0 · Reply
sethmarcus
sethmarcus Jun. 4 at 1:56 PM
If Insiders are buying Health Care $XLV, you should be too? $AMGN $CURE $IBB $UNH
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 4 at 1:37 PM
$AMGN Taking some
0 · Reply
NeverFadeTheOracle
NeverFadeTheOracle Jun. 4 at 1:20 PM
$AMGN Shopping for my meds today
1 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 11:03 AM
0 · Reply
oppel
oppel Jun. 4 at 9:28 AM
$AMGN flying to the air…
0 · Reply
supplySHOCK
supplySHOCK Jun. 4 at 8:13 AM
0 · Reply